GUFIC BIOSCIENCES LIMITED (GUFICBIO): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1YAll

₹474.35 latest close · +21.6% over the last 90 sessions

₹474.35 month-end · +33.4% over 12 months

₹474.35 month-end · +37.0% since Jun '24

52-week range ₹268.00 to ₹480.95 · 1-year volatility 36.6%

Was the rally earned?

+33%share price, 1 yearEarnings and multiple

Both mattered.

Per-share earnings added 20 points and the multiple added 14 points (P/E 57.6x to 64.8x).
The share count barely moved.

Net profit growth+19 ptsNet profit rose about 18%, which lifts the price.

P/E change+14 ptsThe P/E rose from 57.6x to 64.8x, which lifts the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-59.0%recovered 2020-07

1-year volatility36.6%annualised

Beta vs sector index0.933-year daily, correlation 0.35

Volume spikes2last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-59.0% (2019-01 peak to 2020-03 low, recovered 2020-07)

-43.7% (2024-11 peak to 2026-03 low, not yet recovered)

-35.2% (2022-04 peak to 2023-03 low, recovered 2023-08)

Most recent volume spikes

2026-11-09: 10.8x the 50-day median, price +8.7% that day

2026-09-02: 7.4x the 50-day median, price +4.2% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

64.8xP/E todayNear its historic high

Against its own history93rd percentile

CheapestMedian 53.4xDearest

Usual range 41.5x to 63.7x since 2024-06.

Against Health Technology64.8x vs 37.0x

This company

64.8x

Sector median

37.0x

75% above the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE40th▼ 3 pts vs a year ago
Op. margin55th▲ 13 pts vs a year ago
Revenue growth64th▲ 33 pts vs a year ago
EPS growth64th▲ 44 pts vs a year ago
Debt/equity ↓15th▼ 5 pts vs a year ago
Cash cycle ↓31stflat vs a year ago
P/E ↓22ndflat vs a year ago
12M momentum72nd▲ 19 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~30%annual earnings growth implied by the price

At a P/E of 64.8x, the price would imply about 29.6%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹474.35
P/E: 64.8x
ROCE: 12.0%
Market Cap: ₹4752 cr
Revenue (TTM): ₹981 cr
P/S: 4.8x
P/B: 7.1x
ROE: 11.0%
Operating Margin: 18.0%
Debt / Equity: 0.6x
Promoter Holding: 72.5%
12M Momentum: 33.4%

52-week range

₹268.00₹480.95

97% of the way from its 52-week low to its high

Price risk

1Y volatility

36.6%

Beta vs sector

1-year daily

0.95

Balance sheet & cash

Interest cover

operating profit ÷ interest

3.8x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.73x

Share count, 1Y

unchanged

Are profits backed by cash?

5 of 7checks within range2 near a threshold

Other income reliance2%Within range

Other income as a share of pre-tax profit (trailing twelve months): 2.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.73xNear threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.73x (cash from operations ₹161 cr, net profit ₹220 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow2 of 3 yrsNear threshold

Fiscal years with positive free cash flow in the last 3: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-30 daysWithin range

Debtor days are below the median of the previous three fiscal years by 30 days (115 vs 145). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress4% of fixed assetsWithin range

Capital work-in-progress is 4% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+16 days / 2 yrsWithin range

Days payable changed by +16 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, promoters trimmed 2.5 pts; DIIs added 2.0 pts.
The number of shareholders fell from 36,557 to 29,753 (-19%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters75.0%72.5%-2.5 pts

FIIs0.7%0.5%-0.3 pts

DIIs1.6%3.7%+2.0 pts

Public and others22.6%23.4%+0.7 pts

Number of shareholders

29,753shareholders-19% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+1.2%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like GUFIC BIOSCIENCES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −28% to +50% vs the market, against −5% for all non-financial companies in the same months.
The gap against the base rate (+6.2%, 80% range −10.9% to +14.8%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 4 beyond the range shown, drawn at the edge

Similar setups' median

+1.2%

All companies' median

−5.0%

Beat the market

50% vs 44%

50 past situations · 50 companies · 36 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ANURAS Health Technology	Apr 2023	74x	11%	+36%	0%	−50%
ARTEMISMED Health Services	Jan 2025	67x	14%	+71%	−7%	−26%
GREENPANEL Non-Energy Minerals	Jan 2022	93x	12%	+206%	0%	−37%
CRAFTSMAN Producer Manufacturing	Dec 2022	45x	18%	+55%	0%	+22%
PRIVISCL Process Industries	Apr 2025	51x	12%	+57%	−3%	+60%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
LAURUSLABS Health Technology	Feb 2020	47x	8%	+24%	−6%	+211%
ASIANTILES Producer Manufacturing	Aug 2020	43x	11%	+18%	−1%	−60%
GANECOS Process Industries	Nov 2024	98x	8%	+140%	0%	−63%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, 12-month momentum and interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to GUFIC BIOSCIENCES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

PICCADILY AGRO INDUSTRIESPICCADIL

Process Industries

63%similar

debt/equityrevenue

MADHYA BHARAT AGRO PRODUCTMBAPL

Process Industries

55%similar

P/Evolatility

MISHRA DHATU NIGAMMIDHANI

Non-Energy Minerals

53%similar

P/Epromoter holding

ARTEMIS MEDICARE SERVICESARTEMISMED

Health Services

52%similar

market caprevenue

KEYSTONE REALTORSRUSTOMJEE

Finance

51%similar

market capoperating margin

SMS PHARMACEUTICALSSMSPHARMA

Health Technology

51%similar

market caprevenue

BAJAJ HEALTHCAREBAJAJHCARE

Health Technology

42%similar

operating marginP/E

ANUPAM RASAYAN INDIAANURAS

Health Technology

38%similar

debt/equityP/E

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jan '22

2026
NovValuationP/E crossed above the 90th percentile of its own history to date (64.8x).
NovPriceVolume reached 10.8x its 50-day median on 2026-11-09; price +8.7% that day.
SepResultsYear-on-year EPS growth turned positive.
SepPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
SepPriceVolume reached 7.4x its 50-day median on 2026-09-02; price +4.2% that day.
JunValuationP/E crossed above the 90th percentile of its own history to date (63.6x).
JunPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
JunPriceVolume reached 127.6x its 50-day median on 2026-06-30; price +5.4% that day.

Show 22 earlier events

2026
MarPriceFell 44% from the Nov 2024 peak to the Mar 2026 low.
2025
NovPriceVolume reached 7.3x its 50-day median on 2025-11-18; price +5.1% that day.
AugPriceVolume reached 12.3x its 50-day median on 2025-08-20; price +2.8% that day.
JunResultsRevenue (TTM) reached a new high of ₹820 cr.
AprPriceVolume reached 8.1x its 50-day median on 2025-04-24; price +6.5% that day.
MarPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
2024
NovPriceVolume reached 5.7x its 50-day median on 2024-11-04; price +5.8% that day.
AugPriceVolume reached 18.1x its 50-day median on 2024-08-22; price +7.8% that day.
JunPriceVolume reached 17.2x its 50-day median on 2024-06-10; price +19.2% that day.
MarPromoterPromoter holding fell 2.5 pts to 72.5%.
JanPriceVolume reached 6.7x its 50-day median on 2024-01-08; price +1.0% that day.
2023
NovPriceVolume reached 32.3x its 50-day median on 2023-11-30; price +11.5% that day.
AugPriceRegained the 2022-04 peak, 5 months after the low.
JulPriceVolume reached 10.5x its 50-day median on 2023-07-27; price +6.8% that day.
JunPriceVolume reached 32.1x its 50-day median on 2023-06-16; price +13.9% that day.
MarPriceFell 35% from the Apr 2022 peak to the Mar 2023 low.
2022
DecPriceVolume reached 12.5x its 50-day median on 2022-12-29; price +4.1% that day.
SepPriceVolume reached 6.3x its 50-day median on 2022-09-01; price +8.7% that day.
AprPriceRegained the 2022-01 peak, 2 months after the low.
AprPriceVolume reached 22.3x its 50-day median on 2022-04-12; price +8.4% that day.
FebPriceFell 27% from the Jan 2022 peak to the Feb 2022 low.
JanPriceVolume reached 7.4x its 50-day median on 2022-01-12; price +8.8% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history30 months · 2024-06 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	64.8x	₹981 cr	11.0%	12.0%	0.6x
2026-10	56.5x	₹981 cr	11.0%	12.0%	0.6x
2026-09	59.0x	₹981 cr	11.0%	12.0%	0.6x
2026-08	65.1x	₹944 cr	9.6%	12.0%	0.6x
2026-07	60.9x	₹944 cr	9.6%	12.0%	0.6x
2026-06	63.6x	₹944 cr	9.6%	12.0%	0.6x
2026-05	66.9x	₹897 cr	8.3%	13.0%	0.6x
2026-04	57.0x	₹897 cr	8.3%	13.0%	0.6x
2026-03	54.9x	₹897 cr	8.3%	13.0%	0.6x
2026-02	49.8x	₹874 cr	9.5%	13.0%	0.6x
2026-01	54.1x	₹874 cr	9.5%	13.0%	0.6x
2025-12	59.2x	₹874 cr	9.5%	13.0%	0.6x
2025-11	57.6x	₹841 cr	10.3%	13.0%	0.6x
2025-10	52.7x	₹841 cr	10.3%	13.0%	0.6x
2025-09	57.4x	₹841 cr	10.3%	13.0%	0.6x
2025-08	52.8x	₹820 cr	11.6%	13.0%	0.6x
2025-07	57.1x	₹820 cr	11.6%	13.0%	0.6x
2025-06	52.4x	₹820 cr	11.6%	13.0%	0.6x
2025-05	47.8x	₹810 cr	15.4%	—	0.6x
2025-04	45.0x	₹810 cr	15.4%	—	0.6x
2025-03	41.1x	₹810 cr	15.4%	—	0.6x
2025-02	39.0x	₹804 cr	15.9%	—	0.6x
2025-01	53.1x	₹804 cr	15.9%	—	0.6x
2024-12	53.8x	₹804 cr	15.9%	—	0.6x
2024-11	47.6x	₹815 cr	16.1%	—	0.6x
2024-10	50.5x	₹815 cr	16.1%	—	0.6x
2024-09	44.5x	₹815 cr	16.1%	—	0.6x
2024-08	46.8x	₹807 cr	16.1%	—	0.6x
2024-07	41.5x	₹807 cr	16.1%	—	0.6x
2024-06	40.3x	₹807 cr	16.1%	—	0.6x

Methodology and data notes